– USA, MA – Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Dr. Gilmore O’Neill (M.B., M.M.Sc.) as President and CEO, succeeding James C. Mullen who will serve as Executive Chairman, effective June 1, 2022.
“On behalf of the Board of Directors, we are delighted to appoint a leader of Gilmore’s caliber as the Company’s CEO,” said James C. Mullen, Chairman, President, and CEO. “As more of our experimental medicines progress into and through clinical development, Gilmore’s significant drug development experience, proven leadership, passion for genetic medicine, and focus on patients add critical skills to Editas. I look forward to serving as Executive Chairman and partnering closely with Gilmore to ensure continuity and build on the progress Editas has made in service of those living with serious diseases and to deliver value to our shareholders.”
About Dr. Gilmore O’Neill
Dr. O’Neill brings to Editas nearly 20 years of experience in genetic medicine, neurobiology, and clinical development. Dr. O’Neill also has a track record of driving and leading several of biotech’s most successful clinical programs and achieving marketing approvals for several medicines, including Amondys, Vyondys, Spinraza, Plegridy, and Tecfidera. He most recently served as EVP of R&D and CMO at Sarepta Therapeutics. During his tenure at Sarepta, he led the R&D leadership team accountable for creating and driving discovery, preclinical and clinical development, and global regulatory strategy of its RNA and gene therapeutic portfolio. Before that, Dr. O’Neill held several leadership roles at Biogen for over 15 years, most recently serving as SVP responsible for all late-stage clinical development. During his tenure at Biogen, Dr. O’Neill oversaw development programs for rare diseases, gene and cell therapy, neuromuscular disease, pain, multiple sclerosis, acute neurology, movement disorders, and Alzheimer’s disease.
“I’m incredibly excited to join Editas Medicine, which has made significant strides in realizing the potential of gene editing to address previously untreatable diseases,” said Dr. O’Neill. “It is a great privilege to lead the Company and its talented team through its next phase of growth as we continue to transform the platform and advance clinical trials to develop and ultimately commercialize potentially life-changing medicines for people living with serious diseases.”
Dr. O’Neill currently serves as a Board Member at UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, and at Aptinyx Inc., a biotechnology company developing therapies for the treatment of brain and nervous system disorders.
Dr. O’Neill received a Bachelor of Medicine degree from University College Dublin and a Master of Medical Sciences degree from Harvard University. He is licensed to practice medicine in the state of Massachusetts.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.
For more information: https://www.editasmedicine.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
